Interleukin-1 receptor blockade with anakinra provided cessation of fatigue, reduction in inflammation markers and regression of retroperitoneal fibrosis in a patient with Erdheim-Chester disease – case study and a review of literature

Česká verzia

Authors: Z. Adam ¹; P. Szturz ¹; P. Bučková ¹; I. Červinková ²; R. Koukalová ³; Z. Řehák ³; M. Krejčí ¹; L. Pour ¹; L. Zahradová ¹; R. Hájek ¹; Z. Král ¹; J. Mayer ¹
Authors place of work: Interní hematoonkologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Jiří Mayer, CSc. ¹; Radiodiagnostická klinika LF MU a FN Brno, přednosta doc. MUDr. Jarmila Skotáková, Ph. D. ²; Oddělení nukleární medicíny, centrum PET, Masarykův onkologický ústav, prim. MUDr. Karol Bolčák ³
Published in the journal: Vnitř Lék 2012; 58(4): 313-318
Category: Case Reports

Summary

We describe a case of an Erdheim-Chester disease patient. First line chemotherapy treatment with 2-chlorodeoxyadenosine did not reduce fluorodeoxyglucose accumulation in pathological lesions. The patient had continuously increased CRP values of 17–20 mg/l. The disease continued to cause subfebrile temperatures and significant fatigue that made the patient to spend most of the daytime in bed. To manage the permanently increased inflammation markers, we decided to start treatment with anakinra, successfully used in some other autoinflammatory diseases (e.g. Schnitzler syndrome). We have now been able to evaluate the first 6 months of treatment. Daily subcutaneous administration of anakinra (Kineret^TM 100 mg daily) led to normalization of CRP values, cessation of subfebrile temperatures and, importantly, significant reduction of fatigue. Time periods the patient was able to spend out of the bed increased significantly. Consequent to the reduced fatigue, the patient was able to perform basic household tasks he was unable to undertake without treatment. After 3 months of treatment, fatigue of the same intensity returned following a short interruption of therapy. The CRP values went up again to 12 mg/l. CRP value returned back to norm and fatigue ceased after re-initiation of daily Kineret injections. Objective treatment response was assessed by measuring the degree of fluorodeoxyglucose accumulation in pathological bone lesions. PET-CT was performed before and 3 and 6 months after anakinra initiation. Intensity of accumulation did not change significantly after the first 3 months of therapy but decreased after 6 month therapy. Follow up CT of abdominal cavity was performed at the end of the 6th month of treatment. Presented CT images from before and 6 months after the treatment evidence an obvious reduction in fibroid changes in the retroperitoneum. Daily administration of anakinra to a patient with active Erdheim-Chester disease significantly reduced intensity of fatigue and improved quality of life, led to a reduction in inflammatory markers and regression in retroperitoneal fibrotization.

Key words:
anakinra – interleukin-1 receptor blocker – Erdheim-Chester disease – juvenile xantogranuloma – fatigue – autoinflammatory diseases

Zdroje

1. Aouba A, Georgin-Lavialle S, Pagnoux C et al. Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease. Blood 2010; 116: 4070–4076.

2. Adam Z, Balšíková K, Pour L at al. Diabetes insipidus, následovaný po 4 letech dysartrií a lehkou pravostrannou hemiparézou – první klinické příznaky Erdheimovy-Chesterovy nemoci. Popis a zobrazení případu s přehledem informací o této nemoci. Vnitř Lék 2009; 55: 1173–1188.

3. Adam Z, Balšíková K, Krejčí M et al. Centrální diabetes insipidus u dospělých osob – první příznak histiocytózy z Langerhansových buněk a Erdheimovy-Chesterovy choroby. Popis tří případů a přehled literatury. Vnitř Lék 2010; 56: 138–148.

4. Szturz P, Adam Z, Koukalová R et al. Erdheimova-Chesterova nemoc v obrazech. Vnitř Lék 2010; 56 (Suppl 2): 2S170–2S178.

5. Adam Z, Koukalová R, Šprláková A et al. Úspěšná léčba Erdheimovy-Chesterovy nemoci chemoterapií obsahující 2-chlorodeoxyadenosin. Popis dvou případů a přehled literatury. Vnitř Lék 2011; 57: 576–589.

6. Guo J, Wang J. Adult orbital xanthogranulomatous disease: review of the literature. Arch Pathol Lab Med 2009; 133: 1994–1997.

7. Adam Z, Šprláková A, Řehák Z et al. Parciální regrese ložisek Erdheimovy-Chesterovy nemoci v CNS po léčbě 2-chlorodeoxadenosinem a jejich kompletní vymizení při léčbě lenalidomidem. Popis případu a přehled literárních údajů. Klinická Onkologie 2011; v tisku.

8. Arnaud L, Hervier B, Néel A et al. J. CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood 2011; 117: 2778–27782.

9. Jeon IS, Lee SS, Lee MK. Chemotherapy and interferon-alpha treatment of Erdheim-Chester disease. Pediatr Blood Cancer 2010; 55: 745–757.

10. Suzuki HI, Hosoya N, Miyagawa K et al. Erdheim-Chester disease: multisystem involvement and management with interferon-alpha. Leuk Res 2010; 34: e21–e24.

11. Haroche J, Amoura Z, Trad SG et al. Variability in the efficacy of interferon-alpha in Erdheim-Chester disease by patient and site of involvement: results in eight patients. Arthritis Rheum 2006; 54: 3330–3336.

12. Braiteh F, Boxrud C, Esmaeli B et al. Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferon-alpha. Blood 2005; 106: 2992–2994.

13. Arnaud L, Malek Z, Archambaud F et al. 18F-fluorodeoxyglucose-positron emission tomography scanning is more useful in followup than in the initial assessment of patients with Erdheim-Chester disease. Arthritis Rheum 2009; 60: 3128–3138.

14. Steňová E, Steňo B, Povinec P et al. FDG-PET in the Erdheim-Chester disease: its diagnostic and follow-up role. Rheumatol Int 2010 Dec 7. [Epub ahead of print].

15. Janku F, Amin HM, Yang D et al. Response of histiocytoses to imatinib mesylate: fire to ashes. J Clin Oncol 2010; 28: e633–e636.

16. Haroche J, Amoura Z, Charlotte F et al. Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim-Chester histiocytosis. Blood 2008; 111: 5413–5415.

17. Arnaud L, Gorochov G, Charlotte F et al. Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease: a single-center series of 37 patients. Blood 2011; 117: 2783–2790.

18. Toplak N, Dolezalová P, Constantin T. Eastern/Central European autoinflammatory collaborating group for the Paediatric Rheumatology International Trials Organization (PRINTO) and Eurofever Project. Periodic fever syndromes in Eastern and Central European countries: results of a pediatric multinational survey. Pediatr Rheumatol Online J 2010; 8: 29–30.

19. Šedivá A. Poruchy regulace zánětu a periodické horečky. Alergie 2006; 1: 36–41.

20. Schedel J, Bach B, Kümmer-Deschner JB et al. Autoinflamatorische Syndrome/Fiebersyndrome. Hautarzt 2011; 62: 389–402.